High-titre inhibitors in previously untreated patients with severe hemophilia A: an updated estimate of pooled incidence rates in patients treated with plasmaderived concentrates or recombinant Factor VIII Andrea Messori, Valeria Fadda, Dario Maratea, Sabrina Trippoli, Claudio Marinai HTA Unit, ESTAV Toscana Centro, Firenze, Italy Although the relative immunogenicity of plasma-derived vs recombinant Factor VIII (FVIIII) concentrates has been debated for many years (1) (2) (3) , this issue still lacks definitive resolution. A randomized study addressing this question is ongoing (4) , but its results will not be available shortly. In this framework, a close scrutiny of the evidence presently available can be worthwhile. The present analysis was focused specifically on high-titre inhibitors in patients with severe hemophilia A because of the high clinical relevance of this disease condition. At least three systematic reviews have already been published on this topic (1) (2) (3) . The two most recent ones, pubLetter to tHe edItor lished by Iorio et al. (2) and by Franchini et al. (3) , have given quite conflicting results on the incidence of high-titre inhibitors. In fact, Iorio et al. found incidences of 19.4% with recombinant FVIII vs 6.0% for plasma-derived products (P=0.195), while Franchini et al. found 16% vs 14%, respectively (P>0.05) . Although the difference in both comparisons did not reach statistical significance, the risk ratio (RR) found by Iorio (RR=3.23 for recombinant products vs plasma-derived ones, calculated as 19.4%/6.0%) differed considerably from that found by Franchini et al. (RR=1.14) . Likewise, the absolute risk difference was more than 13% according to Iorio et al. (2) as compared to only 2% according to Franchini et al. (3) . More recently, a large-scale observational study by Gouw et al. (4) has reported further information on this topic and has also hypothesized that some differences might exist between different recombinant products. To re-address this issue on the basis of the new data published in recent times (in particular, the study by Gouw et al. (4) ), we undertook a new meta-analysis of observational studies in which the main end-point was the incidence of high-titre inhibitors in patients with severe hemophilia A (5). The first phase of our study was the literature search. The data reported in the previous meta-analyses were eligible for our analysis. In addition, we carried out a Pubmed search that identified all pertinent studies over the period from 1 January 2010 up to 31 August 2013; no literature search before 2010 was carried out because the previous metaanalyses had already identified all pertinent studies of that period. The main criteria for study inclusion were: 1) study carried out in consecutive patients with severe hemophilia A treated with either recombinant FVIII or plasma-derived concentrates; 2) absence of inhibitors at the beginning of the study; 3) information reported on previously untreated patients; 4) measurement of high-titre inhibitors during patients' follow-up; 5) no restrictions in study design in that both retrospective and prospective designs were acceptable as well as single-arm and two-arm studies. In the case of two-arm studies, the two treatment groups (patients treated with plasma-derived concentrates and patients treated with recombinant FVIII) were handled as separate cohorts. Our search was repeated using EM-BASE and Scopus to retrieve any citations missed by Pubmed. High-titre inhibitors were defined as ≥5 Bethesda units. The definition of severe hemophilia relied on the original definition in the individual studies.
After identifying all pertinent studies, a standard observational meta-analysis (or proportion meta-analysis) was carried out focused on the incidence of high-titre inhibitors in severe disease. The statistical model was the randomeffect one (6, 7) . Details about search strategy, study selection and data extraction are reported in Appendix 1. This Appendix provides also more specific information on the meta-analytic models. Our search on PubMed yielded 781 eligible articles, which were scrutinized by two co-authors. After addition of the studies previously identified by the two meta-analysis by Franchini et al. and by Iorio et al. (2, 3) , a total of 44 studies reporting on 3335 patients met our inclusion criteria and were introduced in our analysis. The details on these studies (along with their complete bibliographies) are presented in Appendix 2. In our examination of high-titre inhibitors ( Figure 1 ), our overall analysis of both patient subgroups yielded a pooled rate of 15.6% (95% confidence interval (CI): 13.0% to 18.4%); heterogeneity was large (I 2 =76%). Of more interest is our separate analysis of the two patient subgroups that is also shown in Figure 1 . In the subgroup treated with plasma-derived concentrates, the pooled rate of high-titre inhibitors was 13.1% (95%CI: 9.8% to 16.7%; data from 25 studies and 1694 patients); heterogeneity was at I 2 =77%. The same pooled rate in the subgroup treated with recombinant FVIII was 19.6% (95%CI: 16.1% to 23.3%; data from 19 studies and 1641 patients); heterogeneity was at I 2 =63%. As compared with the two meta-anal-yses published by Iorio et al. (literature search until July 2010; 24 studies; 2094 patients) (2) and by Franchini et al. (search until December 2010; 25 studies; 800 patients) (3), our literature search was extended until August 2013 and therefore included a considerably more extensive data set (44 studies; 3335 patients). This is the main reason why our findings differ to same extent from those previously published. At univariate analysis, our results showed that the incidence of hightitre inhibitors differed between the two types of FVIII; in fact, the statistical difference (t=2.56 df 40, P=0.014) was definitely beyond the conventional threshold of significance (P=0.05). This significant difference was confirmed by a meta-regression analysis of the same data in which the type of Factor VIII acted as a covariate (difference in incidence for recombinant vs plasmaderived factor VIII=+6.4%; 95%CI: +1.4% to +11.3%; P=0.013). Inasmuch as high-titre inhibitors are those most clinically relevant, these findings from our analysis are important and suggest that the development of high-titre inhibitors can be more frequent with recombinant FVIII than with plasma-derived concentrates. Of course, we cannot exclude that our experimental result was affected by the presence of biases (e.g. the more frequent attitude towards inhibitors testing that has occurred in recent years). Anyhow, our finding can raise some concern in this very controversial area, and anyhow deserves to be published. The independent randomized controlled Study on Inhibitors in PlasmaProduct Exposed Toddlers (SIPPET; http://www.clinicaltrials.gov, #NCT 01064284; EUDRACT, #2009-011186-88) is ongoing. Its results are expected to provide further information on this topic with more methodological quality than that of the studies published so far. Finally, after our study had already been completed, a meta-analysis quite similar to ours has been made available (8) . The inclusion criteria adopted by Franchini et al. (8) were more restrictive than ours (e.g. retrospective studies were not eligible), and so Franchini et al. included only 28 prospective studies in their meta-analysis (corresponding to a total of 1421 patients). According to the results by Franchini et al., the incidences of high-titre inhibitors showed no statistically significant difference between the two types of concentrates (16% with plasma-derived concentrates vs 18% with recombinant products; P>0.05). Unfortunately, since the data-sets of included studies were different between our meta-analysis and Franchini's one, it is not possible to determine which factors might have led to these different results (P>0.05 in Franchini's study vs P=0.014 in ours). The availability of both Franchini's meta-analysis and ours can however represent a favorable situation in which duplicate information from meta-analyses (9) and/or systematic reviews can offer a more comprehensive picture of the evidence available on this controversial topic.
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APPENDIX 1
Search strategy, study selection and data extraction. Studies reporting on patients with haemophilia treated with plasma-derived concentrates or recombinant FVIII were identified through a Pubmed search performed using the search terms "haemophil*" and "inhibitor*" (and variants of these terms). This search was supplemented by analysis of the Cochrane Library. We also searched reference lists of included trials and (systematic) reviews, meta-analyses, and health technology assessment reports. We did internet searches to find additional information about the included trials. Two authors (VF, DM) independently screened titles and abstracts according to the inclusion criteria. We included a trial if it met all of the above-mentioned inclusion criteria. Two authors (VF, AM) independently extracted information from each included trial. Discrepancies between authors' assessments were resolved by involvement of a third author (DM). All trials that reported the rate of high-titre inhibitor development in severe disease irrespective of their previous exposure to FVIII source were considered, but only data on previously untreated patients were extracted and analysed. We extracted from each study the information on our primary end-point (incidence of high-titre inhibitors in patients with severe haemophilia) as well as on other characteristics of the patients and of the trial. When we identified more than one publication ofta-an an original trial, we verified that the experimental result was reported only once in our analysis. One approximation that we accepted in our process of data selection was that, depending on the individual study, the definition of severe disease could be either based on baseline Factor VIII<1% or baseline Factor VII<2%. Likewise, although some studies defined high-titre inhibitors as >5BU and others as ≥5BU, our analysis did not differentiate between these two cases, but accepted the original definitions employed in individual trials. Statistical analysis. According to the random effect model, we summarised data on the end-point of our analysis by determining the pooled rate (with 95% confidence interval [95%CI]) in the overall patient series and in the two subgroups treated with either recombinant FVIII or plasma-derived concentrates. Standard proportion meta-analysis (with inverse variance weighting) was employed to estimate these pooled indexes. To improve the reliability of our estimates, the Freeman-Tukey transformation was employed (see Trinquart L, Touzé E. Pitfalls in metaanalysis of observational studies: lessons from a systematic review of the risks of stenting for intracranial atherosclerosis. Stroke. 2009 Oct; 40:e586-7) . We examined heterogeneity with the I 2 statistic. We graded values of I 2 between 0% to 40% as "heterogeneity might not be important", values between 30% and 60% as "moderate heterogeneity", values between 50% and 90% as "substantial heterogeneity", and values between 75% and 100% as "considerable heterogeneity". We used the OMA software (Open Meta-Analyst software, version 4.16.12, Tufts University, url http://tuftscaes.org/open_meta/) for all of our meta-analytic statistical calculations. The t-test for samples of unequal variances was carried out according to the method of Welch-Satterthwaite (see Ruxton GD. The unequal variance t-test is an underused alternative to Student's t-test and the Mann-Whitney U test. Behavioral Ecology 2006, doi:10.1093/beheco/ark016). The results generated by t-test was confirmed by a meta-regression in which the type of Factor VIII acted as a covariate; also this meta-regression was based on the OMA software.
APPENDIX 2
This Appendix includes a figure (Figure A1) showing the results of the analysis on our secondary end-point (rate of inhibitors) and a table (Table A1) reporting detailed information on the studies included in our meta-analysis. Figure 1 • Incidence of high-titre inhibitor development reported in 44 observational studies. Observational meta-analysis (random effect method) was used to evaluate the incidence rates for plasma-derived products (Panel A) and recombinant Factor VIII (Panel B). Black squares denote study-specific rates while diamonds indicate pooled rates; I2 is a measure of heterogeneity (accompanied by its level of statistical significance); the dotted vertical line highlights the pooled incidence. The complete references of the original studies are reported in our Appendix. Abbreviations: R, recombinant Factor VIII; PD, plasmaderived Factor VIII concentrates; Ev, number of events; Trt, number of treated patients. 
